Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $85

Benzinga · 1d ago
Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $95 to $85.